

Cont
A1
92. The method of claim 56, wherein the agent is administered intraperitoneally, orally, subcutaneously, intramuscularly, topically or intravenously.

93. The method of claim 56, wherein the antibody is administered in multiple dosages over a period of at least six months.

94. The method of claim 56, wherein the antibody is administered as a sustained release composition.

95. A monoclonal antibody which specifically binds to an epitope within residues 13-28 of A β wherein the monoclonal antibody is designated as 266.

96. A humanized antibody comprising a humanized antibody which specifically binds to an epitope within residues 13-28 of A β , wherein the humanized antibody is the humanized form of the monoclonal antibody designated as 266.

97. A pharmaceutical composition comprising an antibody which specifically binds to an epitope within residues 13-28 of A β effective to specifically bind to the amyloid deposit or a component thereof to the patient.

98. The pharmaceutical composition of claim 97, wherein the antibody is a humanized antibody.

99. The pharmaceutical composition of claim 96, wherein the antibody is designated as 266.

100. The pharmaceutical composition of claim 99, wherein the antibody is a humanized form of monoclonal antibody 266.

REMARKS

After entry of this Preliminary Amendment, claims 56-100 are pending in the present application, claim 53 having been canceled and claims 56-100 having been added. Claims 56-100 are newly added, but contain no new matter. Support for new claims 56-100 is found throughout the specification, *e.g.*, at page 14, line 14 to page 15, line 3, and, at page 70, line 7 to page 71, line 6. Support for new claims 66, 68, 70, 72, 75, 77, and 78 is also found at page 7, line 6 to line 18. Support for new claim 69 is also found at page 21, lines 27-28. Support


SCHENK, Dale B.
Application No.: 09/724,319
Page 5

PATENT

for new claims 97-100 is also found at page 28, line 11 to line 32. Support for new claims 56-65, 71, 74, 80-94 is also found in claims 1-25, 29-33, and 36-37 of the present application as originally filed. Thus, no new matter is added.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400
Fax: (650) 326-2422
RLC
PA 3164817 v3